Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse

Neurobiology of Disease

Volumn 62, Issue , 2014, Pages 193-207

  Taylor, Tonya N ^a,b   Potgieter, Dawid ^a,b   Anwar, Sabina ^a,b   Senior, Steven L ^a,b   Janezic, Stephanie ^a,b   Threlfell, Sarah ^a,b   Ryan, Brent ^a,b   Parkkinen, Laura ^a   Deltheil, Thierry ^a,b   Cioroch, Milena ^a,b   Livieratos, Achilleas ^b   Oliver, Peter L ^b   Jennings, Katie A ^a,b   Davies, Kay E ^b   Ansorge, Olaf ^a   Bannerman, David M ^a,b   Cragg, Stephanie J ^a,b   Wade Martins, Richard ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Behavior; Dopamine; Norepinephrine; Parkinson's disease; Voltammetry; Synuclein

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; DOPAMINE; NORADRENALIN; TYROSINE 3 MONOOXYGENASE;

ADRENERGIC TRANSMISSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CATECHOLAMINE NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; CYCLIC POTENTIOMETRY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; LEWY BODY; LOCOMOTION; LOCUS CERULEUS; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; STRIA TERMINALIS; SUBSTANTIA NIGRA; TRANSGENIC MOUSE; VENTRAL BED NUCLEUS OF STRIA TERMINALIS;

BEHAVIOR; DOPAMINE; NOREPINEPHRINE; PARKINSON'S DISEASE; VOLTAMMETRY; Α-SYNUCLEIN;

AGE FACTORS; ALPHA-SYNUCLEIN; ANIMALS; BASAL GANGLIA; CHROMOSOMES, ARTIFICIAL, BACTERIAL; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NOREPINEPHRINE; SEPTAL NUCLEI;

EID: 84886427013     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.10.005     Document Type: Article

References (80)

1. Abeliovich A., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25:239-252.
2. Alegre-Abarrategui J., et al. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet. 2009, 18:4022-4034.
3. Al-Wandi A., et al. Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice. Neurobiol. Aging 2010, 31:796-804.
4. Anwar S., et al. Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. J. Neurosci. 2011, 31:7264-7274.
5. Braak H., et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J. Neurol. 2002, 249(Suppl. 3):III/1-5.
6. Braak H., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
7. Cabin D.E., et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 2002, 22:8797-8807.
8. Cabin D.E., et al. Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background. Neurobiol. Aging 2005, 26:25-35.
9. Caudle W.M., et al. Polychlorinated biphenyl-induced reduction of dopamine transporter expression as a precursor to Parkinson's disease-associated dopamine toxicity. Toxicol. Sci. 2006, 92:490-499.
10. Chesselet M.F. In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?. Exp. Neurol. 2008, 209:22-27.
11. Chiba-Falek O., Nussbaum R.L. Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum. Mol. Genet. 2001, 10:3101-3109.
12. Chiba-Falek O., et al. Functional analysis of intra-allelic variation at NACP-Rep1 in the alpha-synuclein gene. Hum. Genet. 2003, 113:426-431.
13. Chiba-Falek O., et al. Regulation of alpha-synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene. Am. J. Hum. Genet. 2005, 76:478-492.
14. Conway K.A., et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:571-576.
15. Cragg S.J. Variable dopamine release probability and short-term plasticity between functional domains of the primate striatum. J. Neurosci. 2003, 23:4378-4385.
16. Cragg S., et al. Heterogeneity of electrically evoked dopamine release and reuptake in substantia nigra, ventral tegmental area, and striatum. J. Neurophysiol. 1997, 77:863-873.
17. Cragg S.J., et al. Dopamine release and uptake dynamics within nonhuman primate striatum in vitro. J. Neurosci. 2000, 20:8209-8217.
18. Cryan J.F., et al. Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:8186-8191.
19. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
20. Dauer W., et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:14524-14529.
21. Deacon R.M., Rawlins J.N. T-maze alternation in the rodent. Nat. Protoc. 2006, 1:7-12.
22. Exley R., et al. Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology 2008, 33:2158-2166.
23. Fernagut P.O., Chesselet M.F. Alpha-synuclein and transgenic mouse models. Neurobiol. Dis. 2004, 17:123-130.
24. Fortin D.L., et al. Lipid rafts mediate the synaptic localization of alpha-synuclein. J. Neurosci. 2004, 24:6715-6723.
25. Freichel C., et al. Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol. Aging 2007, 28:1421-1435.
26. Fu Y., et al. A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse. Brain Struct. Funct. 2012, 217:591-612.
27. Giasson B.I., et al. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002, 34:521-533.
28. Giros B., et al. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379:606-612.
29. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2001, 2:492-501.
30. Gomez-Isla T., et al. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol. Aging 2003, 24:245-258.
31. Jakes R., et al. Identification of two distinct synucleins from human brain. FEBS Lett. 1994, 345:27-32.
32. Jefferson A., Volpi E.V. Fluorescence in situ hybridization (FISH) for genomic investigations in rat. Methods Mol. Biol. 2010, 659:409-426.
33. Jensen P.H., et al. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 1998, 273:26292-26294.
34. Jo E., et al. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. J. Mol. Biol. 2002, 315:799-807.
35. Kilts C.D., Anderson C.M. The simultaneous quantification of dopamine, norepinephrine and epinephrine in micropunched rat brain nuclei by on-line trace enrichment HPLC with electrochemical detection: distribution of catecholamines in the limbic system. Neurochem. Int. 1986, 9:437-445.
36. Knab A.M., et al. Altered dopaminergic profiles: implications for the regulation of voluntary physical activity. Behav. Brain Res. 2009, 204:147-152.
37. Knab A.M., et al. Pharmacological manipulation of the dopaminergic system affects wheel-running activity in differentially active mice. J. Biol. Regul. Homeost. Agents 2012, 26:119-129.
38. Kruger R., et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
39. Kruger R., et al. Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology 2001, 56:1355-1362.
40. Kulnane L.S., et al. Rapid and efficient detection of transgene homozygosity by FISH of mouse fibroblasts. Mamm. Genome 2002, 13:223-226.
41. Kuo Y.M., et al. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum. Mol. Genet. 2010, 19:1633-1650.
42. Langston J.W. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann. Neurol. 2006, 59:591-596.
43. Lee M.K., et al. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 ->Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:8968-8973.
44. Li Z.S., et al. Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice. J. Neurosci. 2006, 26:2798-2807.
45. Matsuoka Y., et al. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 2001, 8:535-539.
46. McCormack A.L., et al. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 2002, 10:119-127.
47. Miles P.R., et al. Release and uptake of catecholamines in the bed nucleus of the stria terminalis measured in the mouse brain slice. Synapse 2002, 44:188-197.
48. Miller G.W., et al. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann. Neurol. 1997, 41:530-539.
49. Miller G.W., et al. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp. Neurol. 1999, 156:138-148.
50. Nemani V.M., et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010, 65:66-79.
51. Neumann M., et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Invest. 2002, 110:1429-1439.
52. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 1999, 22:123-144.
53. Oliver P.L., et al. Disrupted circadian rhythms in a mouse model of schizophrenia. Curr. Biol. 2012, 22:314-319.
54. Outeiro T.F., Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 2003, 302:1772-1775.
55. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, San Diego.
56. Pellow S., et al. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 1985, 14:149-167.
57. Peruzzi P.P., et al. Physiological transgene regulation and functional complementation of a neurological disease gene deficiency in neurons. Mol. Ther. 2009, 17:1517-1526.
58. Platt N.J., et al. Striatal dopamine transmission is subtly modified in human A53Talpha-synuclein overexpressing mice. PLoS One 2012, 7:e36397.
59. Polymeropoulos M.H., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
60. Rathke-Hartlieb S., et al. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice. J. Neurochem. 2001, 77:1181-1184.
61. Reveron M.E., et al. L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice. Neurotoxicology 2002, 23:611-619.
62. Rice M.E., Cragg S.J. Nicotine amplifies reward-related dopamine signals in striatum. Nat. Neurosci. 2004, 7:583-584.
63. Rye D., DeLong M.R. Time to focus on the locus. Arch. Neurol. 2003, 60:320.
64. Schank J.R., et al. Dopamine beta-hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine. Neuropsychopharmacology 2006, 31:2221-2230.
65. Schank J.R., et al. Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety. Biol. Psychiatry 2008, 63:1007-1012.
66. Seidel K., et al. First appraisal of brain pathology owing to A30P mutant alpha-synuclein. Ann. Neurol. 2010, 67:684-689.
67. Senior S.L., et al. Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur. J. Neurosci. 2008, 27:947-957.
68. Specht C.G., Schoepfer R. Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neurosci. 2001, 2:11.
69. Spillantini M.G., et al. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
70. Sulzer D. Clues to how alpha-synuclein damages neurons in Parkinson's disease. Mov. Disord. 2010, 25(Suppl. 1):S27-S31.
71. Taylor T.N., et al. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J. Neurosci. 2009, 29:8103-8113.
72. Thomas B., et al. Resistance to MPTP-neurotoxicity in alpha-synuclein knockout mice is complemented by human alpha-synuclein and associated with increased beta-synuclein and Akt activation. PLoS One 2011, 6:e16706.
73. Tillerson J.L., et al. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp. Neurol. 2002, 178:80-90.
74. Touchman J.W., et al. Human and mouse alpha-synuclein genes: comparative genomic sequence analysis and identification of a novel gene regulatory element. Genome Res. 2001, 11:78-86.
75. Ueda K., et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:11282-11286.
76. van der Putten H., et al. Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 2000, 20:6021-6029.
77. West M.J., et al. Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 1991, 231:482-497.
78. Xia Y., et al. Characterization of the human alpha-synuclein gene: genomic structure, transcription start site, promoter region and polymorphisms. J. Alzheimers Dis. 2001, 3:485-494.
79. Yavich L., et al. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol. Dis. 2005, 20:303-313.
80. Zarranz J.J., et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.